Multiple Sclerosis - Pipeline Review, H1 2020
Multiple Sclerosis - Pipeline Review, H1 2020
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Sclerosis - Pipeline Review, H1 2020, provides an overview of the Multiple Sclerosis (Central Nervous System) pipeline landscape.
Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Sclerosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 14, 21, 41, 2, 195, 38 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 40 molecules, respectively.
Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Sclerosis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Multiple Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Multiple Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Multiple Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Sclerosis (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Multiple Sclerosis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Multiple Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Introduction
Multiple Sclerosis - Overview
Multiple Sclerosis - Therapeutics Development
Multiple Sclerosis - Therapeutics Assessment
Multiple Sclerosis - Companies Involved in Therapeutics Development
Multiple Sclerosis - Drug Profiles
Multiple Sclerosis - Dormant Projects
Multiple Sclerosis - Discontinued Products
Multiple Sclerosis - Product Development Milestones
Appendix
Tables and Figures
List of Tables
Number of Products under Development for Multiple Sclerosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Multiple Sclerosis - Pipeline by 4D Pharma Plc, H1 2020
Multiple Sclerosis - Pipeline by AB Science SA, H1 2020
Multiple Sclerosis - Pipeline by AbbVie Inc, H1 2020
Multiple Sclerosis - Pipeline by Abeome Corp, H1 2020
Multiple Sclerosis - Pipeline by Abion Inc, H1 2020
Multiple Sclerosis - Pipeline by Abivax SA, H1 2020
Multiple Sclerosis - Pipeline by Abreos Biosciences Inc, H1 2020
Multiple Sclerosis - Pipeline by Accure Therapeutics SL, H1 2020
Multiple Sclerosis - Pipeline by Acelerox LLC, H1 2020
Multiple Sclerosis - Pipeline by Actelion Pharmaceuticals Ltd, H1 2020
Multiple Sclerosis - Pipeline by Aequus Pharmaceuticals Inc, H1 2020
Multiple Sclerosis - Pipeline by Affectis Pharmaceuticals AG, H1 2020
Multiple Sclerosis - Pipeline by AgoneX Biopharmaceuticals Inc, H1 2020
Multiple Sclerosis - Pipeline by Ahead Therapeutics SL, H1 2020
Multiple Sclerosis - Pipeline by Akaal Pharma Pty Ltd, H1 2020
Multiple Sclerosis - Pipeline by Alexion Pharmaceuticals Inc, H1 2020
Multiple Sclerosis - Pipeline by Alpha Cancer Technologies Inc, H1 2020
Multiple Sclerosis - Pipeline by Alpine Immune Sciences Inc, H1 2020
Multiple Sclerosis - Pipeline by Altheia Science SRL, H1 2020
Multiple Sclerosis - Pipeline by Amgen Inc, H1 2020
Multiple Sclerosis - Pipeline by Anavex Life Sciences Corp, H1 2020
Multiple Sclerosis - Pipeline by Ankar Pharma SL, H1 2020Multiple Sclerosis - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Multiple Sclerosis - Pipeline by Teikoku Pharma USA Inc, H1 2020
Multiple Sclerosis - Pipeline by Tellus Therapeutics Inc, H1 2020
Multiple Sclerosis - Pipeline by TeraImmune Inc, H1 2020
Multiple Sclerosis - Pipeline by Tetra Therapeutics, H1 2020
Multiple Sclerosis - Pipeline by Theratome Bio Inc, H1 2020
Multiple Sclerosis - Pipeline by Therini Bio Inc, H1 2020
Multiple Sclerosis - Pipeline by Tiziana Life Sciences Plc, H1 2020
Multiple Sclerosis - Pipeline by Toleranzia AB, H1 2020
Multiple Sclerosis - Pipeline by TolerogenixX GmbH, H1 2020
Multiple Sclerosis - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2020
Multiple Sclerosis - Pipeline by Topas Therapeutics GmbH, H1 2020
Multiple Sclerosis - Pipeline by Transparency Life Sciences LLC, H1 2020
Multiple Sclerosis - Pipeline by Trio Medicines Ltd, H1 2020
Multiple Sclerosis - Pipeline by TwotoBiotech Ltd, H1 2020
Multiple Sclerosis - Pipeline by UBI Pharma Inc, H1 2020
Multiple Sclerosis - Pipeline by V Clinbio LLC, H1 2020
Multiple Sclerosis - Pipeline by Vaccinex Inc, H1 2020
Multiple Sclerosis - Pipeline by Vascular Biogenics Ltd, H1 2020
Multiple Sclerosis - Pipeline by Vertex Pharmaceuticals Inc, H1 2020
Multiple Sclerosis - Pipeline by Virogenomics BioDevelopment Inc, H1 2020
Multiple Sclerosis - Pipeline by Virtici LLC, H1 2020
Multiple Sclerosis - Pipeline by Vitalis LLC, H1 2020
Multiple Sclerosis - Pipeline by Vitality Biopharma Inc, H1 2020
Multiple Sclerosis - Pipeline by Xalud Therapeutics Inc, H1 2020
Multiple Sclerosis - Pipeline by Xonovo Inc, H1 2020
Multiple Sclerosis - Pipeline by ZyVersa Therapeutics Inc, H1 2020
Multiple Sclerosis - Dormant Projects, H1 2020
Multiple Sclerosis - Discontinued Products, H1 2020
Multiple Sclerosis - Discontinued Products, H1 2020 (Contd..1), H1 2020
Multiple Sclerosis - Discontinued Products, H1 2020 (Contd..2), H1 2020
Companies Mentioned
4D Pharma Plc
AB Science SA
AbbVie Inc
Abeome Corp
Abion Inc
Abivax SA
Abreos Biosciences Inc
Accure Therapeutics SL
Acelerox LLC
Actelion Pharmaceuticals Ltd
Aequus Pharmaceuticals Inc
Affectis Pharmaceuticals AG
AgoneX Biopharmaceuticals Inc
Ahead Therapeutics SL
Akaal Pharma Pty Ltd
Alexion Pharmaceuticals Inc
Alpha Cancer Technologies Inc
Alpine Immune Sciences Inc
Altheia Science SRL
Amgen Inc
Anavex Life Sciences Corp
Ankar Pharma SL
Anokion SA
Antisense Therapeutics Ltd
AnTolRx Inc
Anvyl LLC
Apaxen
Aphios Corp
Apimeds Inc
Apitope International NV
Aprilbio Co Ltd
Artax Biopharma Inc
Asdera LLC
AstraZeneca Plc
Atara Biotherapeutics Inc
Athersys Inc
Athira Pharma Inc
Atlantic Bio Sci LLC
Autobahn Therapeutics Inc
Autoimmunity Biologic Solutions Inc
Avicanna Inc
Axial Biotherapeutics Inc
Axxam SpA
Barricade Therapeutics Corp
Bayer AG
Baylx Inc
BioAegis Therapeutics Inc
BioApex sro
Biocad
Biocon Ltd
Biocure Technology Inc
Biogen Inc
BioIncept LLC
Biond Biologics Ltd
Biovista Inc
Bolder Biotechnology Inc
Boston Pharmaceuticals Inc
BrainStorm Cell Therapeutics Inc
Bridge Biotherapeutics Inc
Bristol-Myers Squibb Co
BTB Pharma AB
Califia Bio Inc
Cardinal Therapeutics Inc
CavoGene LifeSciences
Cerion LLC
CGeneTech (Suzhou China) Co Ltd
Chipscreen Biosciences Ltd
Cinnagen Co
Clene Nanomedicine Inc
Coherus BioSciences Inc
Commence Bio Inc
Complement Pharma BV
Compugen Ltd
Convelo Therapeutics Inc
Corium, Inc.
Cour Pharmaceuticals Development Co Inc
Curadim Pharma Co Ltd
CuraVac Inc
CuroNZ Ltd
Curyx Bio Inc
Cyteir Therapeutics Inc
Cytocom Inc
Cytodyn Inc
Cyxone AB
DC4U BV
Denali Therapeutics Inc
DiNonA Inc
Disarm Therapeutics Inc
Dr. Reddy's Laboratories Ltd
Druggability Technologies Holdings Ltd
Dualogics Corp
EA Pharma Co Ltd
Eldrug SA
Eli Lilly and Co
Emerald Health Sciences Inc
Endece LLC
EnhanX Biopharm Inc
Enterin Inc
Epitracker Inc
Eton Pharmaceuticals Inc
Evgen Pharma Plc
F. Hoffmann-La Roche Ltd
Farmacija d.o.o. Tuzla
FibroGenesis LLC
Fortuna Fix Inc
Frequency Therapeutics Inc
GABA Therapeutics Inc
Gemac SA
Genervon Biopharmaceuticals LLC
GeNeuro SA
Gilead Sciences Inc
GlaxoSmithKline Plc
Glialogix Inc
Glixis Therapeutics LLC
Glixogen Therapeutics
Handa Pharmaceuticals LLC
Humabs BioMed SA
HuniLife Biotechnology Inc
Hutchison MediPharma Ltd
IL-2Rx Inc
Iltoo Pharma
ImCyse SA
Immune Response BioPharma Inc
Immungenetics AG
Immunic Inc
Immunwork Inc
ImmusanT Inc
Immutep Ltd
Impetis Biosciences Ltd
Imstem Biotechnology Inc
Inflazome Ltd
Inmune Bio Inc
InnoBioscience LLC
Innovimmune Biotherapeutics Inc
InSight Biopharmaceuticals Ltd
Io Therapeutics Inc
Istesso Ltd
J2H Biotech
Jura Bio Inc
Jyant Technologies Inc
Karo Pharma AB
Klogene Therapeutics Inc
Kogenix Therapeutics Inc
Kyorin Pharmaceutical Co Ltd
Landos Biopharma Inc
Lead Discovery Center GmbH
Leukosight Inc
LFB SA
LIFNano Rx Ltd
Llama Therapeutics Inc
Mabion SA
MAKScientific LLC
Mapi Pharma Ltd
Maruho Co Ltd
Med-Life Discoveries LP
MedAnnex Ltd
MedDay SA
Medicenna Therapeutics Corp
Merck KGaA
Meta-IQ ApS
MetiMedi Pharmaceuticals Co Ltd
MetrioPharm AG
Millennium Pharmaceuticals Inc
Mirae Cell Bio Co Ltd
Mitochon Pharmaceuticals Inc
Mitotech SA
Mitsubishi Tanabe Pharma Corp
MMJ International Holdings Corp
Mochida Pharmaceutical Co Ltd
Molecules For Health Inc
MorphoSys AG
Mount Tam Biotechnologies Inc
MyMD Pharmaceuticals Inc
NervGen Pharma Corp
Neuren Pharmaceuticals Ltd
Neuro Vigor LLC
Neurodegeneration Therapeutics Inc
Neurotrope Bioscience Inc
New World Laboratories Inc
Novartis AG
Novoron Bioscience Inc
Numab Therapeutics AG
Omeros Corp
Oncodesign SA
OncoImmune Inc
Op-T-Mune Inc
Orion Biotechnology Canada Ltd
Orpheris Inc
Oryzon Genomics SA
Oscine Therapeutics
OSE Immunotherapeutics
Ossianix Inc
Pahan Therapeutics
Pangen Biotech Inc
Par'Immune SAS
Parkside Scientific Inc
PharmatrophiX Inc
PharmCADD Co Ltd
Pheno Therapeutics Ltd
Pipeline Therapeutics Inc
Polpharma Biologics
PolTREG Sp z o o
Principia Biopharma Inc
Progenitor Therapeutics Ltd
Promethera Biosciences SA
ProNoxis AB
Proteorex Therapeutics Inc
Provid Pharmaceuticals Inc
Q Therapeutics Inc
Quimatryx SL
Reata Pharmaceuticals Inc
ReceptoPharm Inc
RedHill Biopharma Ltd
RegeneRx Biopharmaceuticals Inc
RemeGen Ltd
ReNeuroGen LLC
Renovo Neural Inc
Resverlogix Corp
Revalesio Corp
Reven Pharmaceuticals Inc
ReveraGen BioPharma Inc
Rewind Therapeutics NV
Rhizen Pharmaceuticals SA
Rigel Pharmaceuticals Inc
Riptide Bioscience Inc
Rodos BioTarget GmbH
Rubius Therapeutics Inc
SanBio Company Limited
Sangamo Therapeutics Inc
Sanofi
Sansho Co Ltd
Sarepta Therapeutics Inc
Sareum Holdings Plc
Scientus Pharma Inc
Seneca Biopharma Inc
Senju Pharmaceutical Co Ltd
Senzer Ltd
SK Chemicals Co Ltd
Stem Cell Medicine Ltd
Sujana Biotech, LLC
Suzhou Connect Biopharmaceuticals Ltd
Symbiotix Biotherapies Inc
SynAct Pharma AB
Takeda Pharmaceutical Co Ltd
Teikoku Pharma USA Inc
Tellus Therapeutics Inc
TeraImmune Inc
Tetra Therapeutics
Theratome Bio Inc
Therini Bio Inc
Tiziana Life Sciences Plc
Toleranzia AB
TolerogenixX GmbH
Tonix Pharmaceuticals Holding Corp
Topas Therapeutics GmbH
Transparency Life Sciences LLC
Trio Medicines Ltd
TwotoBiotech Ltd
UBI Pharma Inc
V Clinbio LLC
Vaccinex Inc
Vascular Biogenics Ltd
Vertex Pharmaceuticals Inc
Virogenomics BioDevelopment Inc
Virtici LLC
Vitalis LLC
Vitality Biopharma Inc
Xalud Therapeutics Inc
Xonovo Inc
ZyVersa Therapeutics Inc
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets